title: [Prognosis value of p53 gene and cellular proliferation factors in malignant supratentorial gliomas].
abstract: OBJECTIVE
  The aim of this study was to investigate prognosis value of p53 oncosuppresor gene and labeling index by MIB-1 and PCNA monoclonal antibodies in malignant gliomas.
  
  
  RESULTS
  We operated 60 patient with malignant glioma between July 1994 and August 1998. Forty-five cases had the histopathological diagnosis of Glioblastoma Multiforme and fifteen cases of anaplastic astrocytoma or olygoastrocytoma. Initially we compare MIB-1/PCNA labeling index in eighteen cases. Patients < 40 years old, short period of symptoms preoperatively, only one cerebral lobe localization, total surgical exeresis, Karnofsky index > 70 postoperatively, low labeling index (MIB < 8.6%), forward radiotherapy treatment and surgical re-operation, were identified like favourable outcome factors in the uninvariable analysis. However to the multivariable analysis, only had outcome significance: patients < 40 years old, low labeling index, Karnofsky index > 70 postoperatively and surgical reoperation.
  
  
  CONCLUSIONS
  On the basis of the results of current analysis, moreover classical factors associated with better outcome, low labeling index to Glioblastoma Multiforme have been noted in patients with longer survival, and must be included to conventional histopathological studies.
authors.affiliation: Servicio de Neurocirugía, Hospital General de Castellón.
authors.forename: J L
authors.initials: JL
authors.lastname: Gil-Salú
authors.forename: J M
authors.initials: JM
authors.lastname: González-Darder
authors.forename: J A
authors.initials: JA
authors.lastname: Barcia Albacar
authors.forename: J V
authors.initials: JV
authors.lastname: Pesudo
authors.forename: J M
authors.initials: JM
authors.lastname: Vera-Román
authors.forename: R
authors.initials: R
authors.lastname: Lázaro
authors.forename: M
authors.initials: M
authors.lastname: Alós
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000378:metabolism; D034961:Antigens, Nuclear; D001932:Brain Neoplasms / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D002465:Cell Movement; D003131:Combined Modality Therapy; D016158:Genes, p53 / Q000235:genetics*; D005910:Glioma / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D006801:Humans; D017567:Karnofsky Performance Status; D019394:Ki-67 Antigen; D008875:Middle Aged; D009687:Nuclear Proteins / Q000378:metabolism; D011184:Postoperative Period; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism*; D012189:Retrospective Studies; D015173:Supratentorial Neoplasms / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D014407:Tumor Cells, Cultured / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D034961:Antigens, Nuclear; D019394:Ki-67 Antigen; D009687:Nuclear Proteins; D018809:Proliferating Cell Nuclear Antigen